These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 15951290

  • 1. Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia.
    Ferrara F, D'Arco AM, De Simone M, Mele G, Califano C, Pocali B, Danise P, Palmieri S.
    Haematologica; 2005 Jun; 90(6):776-84. PubMed ID: 15951290
    [Abstract] [Full Text] [Related]

  • 2. Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome.
    Ferrara F, Palmieri S, Izzo T, Criscuolo C, Riccardi C.
    Hematol Oncol; 2010 Dec; 28(4):202-8. PubMed ID: 21136583
    [Abstract] [Full Text] [Related]

  • 3. Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
    Clavio M, Gatto S, Beltrami G, Quintino S, Canepa L, Pierri I, Galbusera V, Carrara P, Miglino M, Varaldo R, Ballerini F, Venturino C, Cerri R, Risso M, Balleari E, Carella AM, Sessarego M, Ghio R, Bacigalupo A, Gobbi M.
    J Exp Clin Cancer Res; 2002 Dec; 21(4):481-7. PubMed ID: 12636093
    [Abstract] [Full Text] [Related]

  • 4. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
    Camera A, Rinaldi CR, Palmieri S, Cantore N, Mele G, Mettivier V, Miraglia E, Mastrullo L, Grimaldi F, Luciano L, Guerriero A, Rotoli B, Ferrara F.
    Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
    [Abstract] [Full Text] [Related]

  • 5. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
    Hołowiecki J, Grosicki S, Kyrcz-Krzemien S, Skotnicki AB, Piatkowska-Jakubas B, Warzocha K, Seferynska I, Zdziarska B.
    Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
    [Abstract] [Full Text] [Related]

  • 6. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ.
    J Clin Oncol; 2005 Aug 20; 23(24):5675-87. PubMed ID: 16110027
    [Abstract] [Full Text] [Related]

  • 7. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
    Russo D, Malagola M, de Vivo A, Fiacchini M, Martinelli G, Piccaluga PP, Damiani D, Candoni A, Michielutti A, Castelli M, Testoni N, Ottaviani E, Rondoni M, Pricolo G, Mazza P, Zuffa E, Zaccaria A, Raspadori D, Bocchia M, Lauria F, Bonini A, Avanzini P, Gugliotta L, Visani G, Fanin R, Baccarani M.
    Br J Haematol; 2005 Oct 20; 131(2):172-9. PubMed ID: 16197446
    [Abstract] [Full Text] [Related]

  • 8. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
    Oriol A, Ribera JM, Esteve J, Guàrdia R, Brunet S, Bueno J, Pedro C, Llorente A, Tormo M, Besalduch J, Sánchez JM, Batlle M, Vivancos P, Carreras E, Vilà JM, Julià A, Sierra J, Montserrat E, Feliu E, CETLAM AML-99.
    Haematologica; 2004 Jul 20; 89(7):791-800. PubMed ID: 15257930
    [Abstract] [Full Text] [Related]

  • 9. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
    You Y, Li QB, Chen ZC, Li WM, Xia LH, Zhou H, Zou P.
    Chin Med J (Engl); 2008 Sep 20; 121(18):1770-4. PubMed ID: 19080355
    [Abstract] [Full Text] [Related]

  • 10. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY, Yang LJ, Xu B, Liu XL, Zheng WY, Zhang Y, Huang F, Sun J, Liu QF.
    Ai Zheng; 2003 Dec 20; 22(12):1330-3. PubMed ID: 14693062
    [Abstract] [Full Text] [Related]

  • 11. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W.
    Clin Cancer Res; 1995 Feb 20; 1(2):169-78. PubMed ID: 9815970
    [Abstract] [Full Text] [Related]

  • 12. Continuous infusion of intermediate-dose cytarabine and fludarabine with idarubicin for patients younger than 60 years with resistant acute myeloid leukemia: a prospective, multicenter phase II study.
    Kim H, Park JH, Lee JH, Lee JH, Joo YD, Lee WS, Bae SH, Mo Ryoo H, Lee KH, Cooperative Study Group A for Hematology.
    Am J Hematol; 2009 Mar 20; 84(3):161-6. PubMed ID: 19195034
    [Abstract] [Full Text] [Related]

  • 13. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
    Pastore D, Specchia G, Carluccio P, Liso A, Mestice A, Rizzi R, Greco G, Buquicchio C, Liso V.
    Ann Hematol; 2003 Apr 20; 82(4):231-5. PubMed ID: 12707726
    [Abstract] [Full Text] [Related]

  • 14. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia.
    Tsimberidou AM, Stavroyianni N, Viniou N, Papaioannou M, Tiniakou M, Marinakis T, Skandali A, Sakellari I, Yataganas X, Hellenic Cooperative Group.
    Cancer; 2003 Apr 01; 97(7):1721-31. PubMed ID: 12655529
    [Abstract] [Full Text] [Related]

  • 15. GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly.
    Pierri I, Clavio M, Beltrami G, Cavaliere M, Lanza L, Miglino M, Canepa L, Pietrasanta D, Ballerini F, Quintino S, Gatto S, Celesti L, Carrara P, Varese P, Gobbi M.
    J Exp Clin Cancer Res; 1999 Mar 01; 18(1):55-60. PubMed ID: 10374678
    [Abstract] [Full Text] [Related]

  • 16. Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia.
    Lashkari A, Lowe T, Collisson E, Paquette R, Emmanouilides C, Territo M, Schiller G.
    Biol Blood Marrow Transplant; 2006 Apr 01; 12(4):466-71. PubMed ID: 16545730
    [Abstract] [Full Text] [Related]

  • 17. A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.
    Bolaños-Meade J, Guo C, Gojo I, Karp JE.
    Leuk Res; 2004 Jun 01; 28(6):571-7. PubMed ID: 15120933
    [Abstract] [Full Text] [Related]

  • 18. A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5).
    Sperr WR, Piribauer M, Wimazal F, Fonatsch C, Thalhammer-Scherrer R, Schwarzinger I, Geissler K, Knöbl P, Jäger U, Lechner K, Valent P.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 1):3965-71. PubMed ID: 15217926
    [Abstract] [Full Text] [Related]

  • 19. A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.
    Koc Y, Oyan B, Kars A, Tekuzman G, Canpinar H, Kansu E.
    Hematol Oncol; 2004 Jun 15; 22(2):43-53. PubMed ID: 15386563
    [Abstract] [Full Text] [Related]

  • 20. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
    Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM, Estey E, Beran M.
    Leuk Res; 2004 Apr 15; 28(4):353-7. PubMed ID: 15109534
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.